Gaillard R C, Schoenenberg P, Favrod-Coune C A, Muller A F, Marie J, Bockaert J, Jard S
Proc Natl Acad Sci U S A. 1984 May;81(9):2907-11. doi: 10.1073/pnas.81.9.2907.
Crude plasma membrane fractions were prepared from female Wistar rat anterior pituitaries. These fractions contained a single population of specific 3H-labeled [8-lysine]vasopressin [( 3H]vasopressin) binding sites with a dissociation of constant (Kd) of 8 +/- 2 X 10(-9) M and maximal binding capacity of 244 +/- 45 fmol/mg of protein. The Kd values for a series of vasopressin structural analogues with selective vasopressor or antidiuretic activities were determined together with the corresponding corticotropin-releasing activities (isolated perfused pituitary cells were used). A good correspondence was found between the two sets of values, suggesting that the detected vasopressin binding sites are the receptors involved in vasopressin-induced corticotropin release. The order of potency of these analogues for the binding to hypophysial receptors was similar to that found for the binding to the receptors involved in the vasopressor response. Corticotropin-releasing factor and angiotensin did not affect vasopressin binding to pituitary membranes. Median eminence extracts inhibited [3H]vasopressin binding with an efficiency very close to that expected from their vasopressin content. Corticotropin-releasing factor activated, and angiotensin inhibited, the adenylate cyclase activity of pituitary membranes. Under the same experimental conditions, vasopressin did not influence adenylate cyclase activity nor did it affect the corticotropin-releasing factor-induced activation. These data support the view that vasopressin is one component of the multifactorial regulation of corticotropin release and that it acts through a cAMP-independent pathway. The potentiation by vasopressin of corticotropin-releasing factor-induced cAMP accumulation in intact cells very likely proceeds through indirect mechanisms, which are not expressed in broken cell preparations.
从雌性Wistar大鼠的垂体前叶制备粗制质膜组分。这些组分含有单一群体的特异性3H标记的[8-赖氨酸]加压素[(3H)加压素]结合位点,其解离常数(Kd)为8±2×10-9M,最大结合容量为244±45fmol/mg蛋白质。测定了一系列具有选择性血管升压或抗利尿活性的加压素结构类似物的Kd值以及相应的促肾上腺皮质激素释放活性(使用分离灌注的垂体细胞)。发现两组值之间有良好的对应关系,表明检测到的加压素结合位点是参与加压素诱导的促肾上腺皮质激素释放的受体。这些类似物与垂体受体结合的效力顺序与在血管升压反应中涉及的受体结合所发现的顺序相似。促肾上腺皮质激素释放因子和血管紧张素不影响加压素与垂体膜的结合。正中隆起提取物抑制[3H]加压素结合,其效率与根据其加压素含量预期的效率非常接近。促肾上腺皮质激素释放因子激活垂体膜的腺苷酸环化酶活性,而血管紧张素抑制该活性。在相同的实验条件下,加压素不影响腺苷酸环化酶活性,也不影响促肾上腺皮质激素释放因子诱导的激活。这些数据支持这样的观点,即加压素是促肾上腺皮质激素释放多因素调节的一个组成部分,并且它通过不依赖cAMP的途径起作用。加压素对完整细胞中促肾上腺皮质激素释放因子诱导的cAMP积累的增强作用很可能通过间接机制进行,而这些机制在破碎细胞制剂中不表达。